Payment overview · 2025
General Payments
$2,797.20
78 reported records · 19 companies
Healthcare provider profile · identity verified
Paul York Cunningham, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · SHENANDOAH, TX · NPI 1356582886
Verified facts
What the public records show
CMS Open Payments records show Paul York Cunningham, M.D. received $2,797.20 in general payments during 2025 across 78 reported records.
Medtronic, Inc. accounted for 21.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 774 claims for Eliquis by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$596.02 | 21.3% | 10 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $324.52 | 11.6% | 6 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $289.61 | 10.3% | 10 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $269.80 | 9.7% | 10 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $254.27 | 9.1% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $228.90 | 8.2% | 7 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $185.32 | 6.6% | 9 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $169.84 | 6.1% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $158.87 | 5.7% | 7 | 2025 |
| LEO Pharma Inc. | Unresolved — no canonical attribution shown | $62.95 | 2.2% | 1 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $55.44 | 2.0% | 1 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $36.07 | 1.3% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $29.77 | 1.1% | 2 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $28.74 | 1.0% | 1 | 2025 |
| COLOPLAST CORP | Unresolved — no canonical attribution shown | $26.92 | 1.0% | 1 | 2025 |
| LeMaitre Vascular, Inc. | Unresolved — no canonical attribution shown | $24.53 | 0.9% | 1 | 2025 |
| Urgo Medical North America, LLC | Unresolved — no canonical attribution shown | $23.14 | 0.8% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $18.27 | 0.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.22 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,797.20 | 78 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $243.77 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $185.32 | 9 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $173.06 | 5 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $169.84 | 5 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $168.00 | 4 | 2025 |
Source payment records
|
|||||
| STRAVIX Normalized: stravix |
Biological | Smith+Nephew, Inc. | $165.13 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $158.87 | 7 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $153.27 | 3 | 2025 |
Source payment records
|
|||||
| LINQ II Normalized: linq ii |
Device | Medtronic, Inc. | $146.39 | 1 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $140.22 | 4 | 2025 |
Source payment records
|
|||||
| Varithena Administration Pack Normalized: varithena administration pack |
Device | Boston Scientific Corporation | $108.14 | 4 | 2025 |
Source payment records
|
|||||
| AMPLATZER AMULET Normalized: amplatzer amulet |
Device | Abbott Laboratories | $98.89 | 1 | 2025 |
Source payment records
|
|||||
| GRAFIX PL Normalized: grafix pl |
Biological | Smith+Nephew, Inc. | $82.80 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $75.63 | 4 | 2025 |
Source payment records
|
|||||
| SPEVIGO Normalized: spevigo |
Biological | LEO Pharma Inc. | $62.95 | 1 | 2025 |
Source payment records
|
|||||
| TENDRIL Normalized: tendril |
Device | Abbott Laboratories | $57.63 | 1 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $55.44 | 1 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $55.44 | 1 | 2025 |
Source payment records
|
|||||
| SYNERGY ABLATION SYSTEM Normalized: synergy ablation system |
Device | AtriCure, Inc. | $36.07 | 1 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $33.56 | 1 | 2025 |
Source payment records
|
|||||
| ACCUGUIDE Normalized: accuguide |
Device | Medtronic, Inc. | $32.08 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $29.77 | 2 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $28.74 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $28.74 | 1 | 2025 |
Source payment records
|
|||||
| Biatain Ag Non-Adhesive Normalized: biatain ag non adhesive |
Device | COLOPLAST CORP | $26.92 | 1 | 2025 |
Source payment records
|
|||||
| ARTEGRAFT VASCULAR GRAFT Normalized: artegraft vascular graft |
Device | LeMaitre Vascular, Inc. | $24.53 | 1 | 2025 |
Source payment records
|
|||||
| URGOCLEAN AG Normalized: urgoclean ag |
Device | Urgo Medical North America, LLC | $23.14 | 1 | 2025 |
Source payment records
|
|||||
| RENASYS TOUCH Normalized: renasys touch |
Device | Smith+Nephew, Inc. | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.22 | 1 | 2025 |
Source payment records
|
|||||
| BodyGuardian Normalized: bodyguardian |
Device | Boston Scientific Corporation | $8.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 774 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 65 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
65 | 22 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
774 | 186 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
78 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1037 | 334 |
| Metoprolol Succinate | Metoprolol Succinate | 894 | 286 |
| Eliquis | Apixaban | 774 | 186 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 589 | 199 |
| Clopidogrel | Clopidogrel Bisulfate | 526 | 179 |
| Valsartan | Valsartan | 456 | 153 |
| Amlodipine Besylate | Amlodipine Besylate | 455 | 164 |
| Furosemide | Furosemide | 432 | 172 |
| Carvedilol | Carvedilol | 391 | 129 |
| Losartan Potassium | Losartan Potassium | 383 | 132 |
| Lisinopril | Lisinopril | 363 | 113 |
| Xarelto | Rivaroxaban | 349 | 87 |
| Nifedipine Er | Nifedipine | 327 | 106 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 226 | 72 |
| Metoprolol Tartrate | Metoprolol Tartrate | 225 | 77 |
| Ezetimibe | Ezetimibe | 200 | 69 |
| Repatha Sureclick | Evolocumab | 198 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 153 | 52 |
| Hydralazine Hcl | Hydralazine Hcl | 132 | 46 |
| Spironolactone | Spironolactone | 110 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 108 | 31 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 102 | 31 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 98 | 30 |
| Potassium Chloride | Potassium Chloride | 90 | 34 |
| Atenolol | Atenolol | 85 | 25 |
| Warfarin Sodium | Warfarin Sodium | 84 | 20 |
| Ranolazine Er | Ranolazine | 80 | 24 |
| Simvastatin | Simvastatin | 80 | 27 |
| Entresto | Sacubitril/Valsartan | 78 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 24 |
| Flecainide Acetate | Flecainide Acetate | 71 | 24 |
| Nebivolol Hcl | Nebivolol Hcl | 69 | 24 |
| Jardiance | Empagliflozin | 65 | 22 |
| Clonidine Hcl | Clonidine Hcl | 64 | 36 |
| Ramipril | Ramipril | 60 | 17 |
| Amiodarone Hcl | Amiodarone Hcl | 57 | 21 |
| Nitroglycerin | Nitroglycerin | 56 | 33 |
| Praluent Pen | Alirocumab | 54 | 13 |
| Brilinta | Ticagrelor | 46 | 13 |
| Irbesartan | Irbesartan | 38 | 12 |
| Telmisartan | Telmisartan | 38 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 35 | 14 |
| Propranolol Hcl | Propranolol Hcl | 35 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | 11 |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Minoxidil | Minoxidil | 28 | suppressed |
| Repatha Syringe | Evolocumab | 26 | suppressed |
| Omeprazole | Omeprazole | 25 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 22 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Jantoven | Warfarin Sodium | 21 | suppressed |
| Sotalol | Sotalol Hcl | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 19 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Gabapentin | Gabapentin | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Repatha Pushtronex | Evolocumab | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 13 | suppressed |
| Multaq | Dronedarone Hcl | 13 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Allopurinol | Allopurinol | 11 | suppressed |
| Famotidine | Famotidine | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Toprol Xl | Metoprolol Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,797.20 · 78 records | Medtronic, Inc. | ACCUGUIDE, AMPLATZER AMULET, ARTEGRAFT VASCULAR GRAFT, Biatain Ag Non-Adhesive, BodyGuardian, CAMZYOS, CARDIOMEMS, ELIQUIS, ENDOCROSS Device, GRAFIX PL, HAWKONE, INSPIRE, JARDIANCE, LEQVIO, LINQ II, LifeVest, OPSYNVI, RENASYS TOUCH, REPATHA, SPEVIGO, STRAVIX, SYMPLICITY G3, SYNERGY ABLATION SYSTEM, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, TENDRIL, Torus Stent Graft System, UPTRAVI, URGOCLEAN AG, VENASEAL, Varithena Administration Pack, WATCHMAN FLX | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error